Dainippon Sumitomo looking for new Sunovion CEO following Iwicki departure
This article was originally published in Scrip
Mark Iwicki, the president and CEO of Dainippon Sumitomo Pharmaceuticals' (DSP) US subsidiary Sunovion Pharmaceuticals, has resigned his positions with the company.
The Japanese firm told Scrip that Mr Iwicki had decided "to pursue other interests" and that it had named Sunovion's chief financial officer, executive vice-president and vice-chairman Hiroshi Nomura as caretaker president and CEO of the operation.
Mr Iwicki was formerly chief operating officer of Sunovion, the renamed Sepracor that was acquired by DSP in 2009 for $2.6 billion. He has worked previously at several other firms including Novartis and Merck.